Home Newsfeeds Raymond James Maintains Outperform on Vertex, Raises Price Target to $22

Raymond James Maintains Outperform on Vertex, Raises Price Target to $22

Raymond James analyst Alexander Sklar maintains Vertex (NASDAQ:VERX) with a Outperform and raises the price target from $19 to $22.

byBenzinga Newsdesk

March 9, 2023

1 minute read

Raymond James analyst Alexander Sklar maintains Vertex (NASDAQ:VERX) with a Outperform and raises the price target from $19 to $22.

Benzinga Before The Bell: Meta Loses Key Metaverse Official, US Government To Cancel Free At-Home COVID Tests, Singapore Mulls Rules To Regulate Cryptocurrency Trading And Other Top Financial Stories Monday, August 29

By Akanksha Bakshi

August 29, 8:42 AM

CNBC No More Free COVID-19 At-Home Tests, Federal Government Says

AAPL

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions In Patients With Diabetes

By Benzinga Newsdesk

April 4, 8:02 AM

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data show that inhibiting

ZVSA

Bill Ford’s Plea To End UAW Strike, Analysts See Near-Term Buying Opportunity On US Automaker Stocks

By Piero Cingari

October 16, 5:01 PM

Bill Ford encourages union leaders and members to work together with the company to reach a resolution, as CNBC reported.

News

Pacific Gas & Electric To Join S&P 500 As Vista Equity Scoops Citrix Systems

By Anusuya Lahiri

September 26, 10:54 AM

Pacific Gas & Electric Co (NYSE:PCG) will replace Citrix Systems, Inc (NASDAQ:CTXS) in the S&P 500, effective before the market opens on…

CTXS

Raymond James Maintains Outperform on Vertex, Raises Price Target to $22

Related Posts

Benzinga Before The Bell: Meta Loses Key Metaverse Official, US Government To Cancel Free At-Home COVID Tests, Singapore Mulls Rules To Regulate Cryptocurrency Trading And Other Top Financial Stories Monday, August 29

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions In Patients With Diabetes

Bill Ford’s Plea To End UAW Strike, Analysts See Near-Term Buying Opportunity On US Automaker Stocks

Pacific Gas & Electric To Join S&P 500 As Vista Equity Scoops Citrix Systems